There are 437 papers on ovarian cancer in aging research: 15 trials and 193 observational studies in people, 24 in animals, 15 in cells, 139 reviews.
437 papers study it206 more mention it144 findings
44 new papers in 30 daysSee all 643 papers on ovarian cancer
At a glance
Advanced age increases ovarian cancer formation and volume in a rat study, and cellular senescence promotes ovarian cancer in a human-cell study. Human studies link later menopause and pathogenic BRCA1 or BRCA2 variants with higher ovarian cancer risk, while telomere-length associations point both ways.
144 findings in 101 papers from 2007 to 2026, 36 of them since April 2026
“later menopause (at age ≥55 years; HR, 1.36 [95% CI, 1.11-1.66]), longer reproductive span (≥40 years; HR, 1.21 [95% CI, 1.09-1.34]),”
- Human trial15
- Humans193
- Animals24
- Cells15
- In silico43
Interventions
8Lactation
no changein humans1HR 0.94
1 study
Lactation
no changein humans1HR 0.94
Lactation was not clearly linked with ovarian cancer in humans (HR 0.94, 95% CI: 0.82-1.09).
“ovarian (0.94 [0.82-1.09] per month)”
Humansfemalesn = 6,880
Maternal & child nutrition
Hedgehog signaling inhibitors
downin mice1
1 study
Hedgehog signaling inhibitors
downin mice1
Hedgehog signaling inhibitors decrease ovarian cancer in aged mice bearing ovarian cancer.
“Pharmacologic Hedgehog inhibition in aged mice suppressed tumor growth, reduced metastasis”
Animalsin aged mice bearing ovarian cancerfemales
Ovarian cancer grew and spread more in older mice
bioRxiv : the preprint server for biologyPreprint
Salpingectomy
downin humans1
1 study
Salpingectomy
downin humans1
Salpingectomy prevents ovarian cancer in humans during indicated benign surgery.
“Opportunistic salpingectomy during indicated benign surgery is supported as an ovarian cancer prevention strategy that preserves ovarian hormonal function”
Reviewduring indicated benign surgery
Complex benign gynecology in perimenopause: current evidence and future directions
Current opinion in obstetrics & gynecology
Aspirin
downin humans1
1 study
Aspirin
downin humans1
Aspirin protects against ovarian cancer in humans.
“Long-term aspirin usage had a moderate protective effect against ovarian cancer”
Reviewlong-term
Aspirin's Dual Role in Cancer: A Systematic Review of the Current Evidence
International Journal of Drug Delivery Technology
Prophylactic salpingo-oophorectomy
downin humans1
1 study
Prophylactic salpingo-oophorectomy
downin humans1
Prophylactic salpingo-oophorectomy is linked with lower ovarian cancer in humans (incidental findings in BRCA1 and BRCA2 carriers after PBSO) (2.0% (6 of 293) incidental ovarian cancer or STIC; 1.7% gBRCA1, 0.3% gBRCA2).
“with 6 women having an incidental finding of ovarian cancer and STIC respectively (=2.0%; 1.7% gBRCA1 and 0.3% gBRCA2)”
Humansincidental findings in BRCA1 and BRCA2 carriers after PBSOovaryfemalesn = 293
Cancer medicine
Coffee
no changein humans1
1 study
Coffee
no changein humans1
Coffee showed no clear effect on ovarian cancer in humans.
“However, no statistical association was found between coffee and ovarian cancer.”
Review
COFFEE CONSUMPTION AND FEMALE CANCERS: A NARRATIVE REVIEW OF RECENT EVIDENCE
EuroMediterranean Biomedical Journal
Risk-reducing salpingo-oophorectomy
downin humans1
1 study
Risk-reducing salpingo-oophorectomy
downin humans1
Risk-reducing salpingo-oophorectomy prevents ovarian cancer in women at increased risk.
“Women at increased risk can choose to have an operation to remove the fallopian tubes and ovaries, which is the most effective way to prevent ovarian cancer.”
Reviewin women at increased riskfemales
BJOG : an international journal of obstetrics and gynaecology
Risk-reducing bilateral salpingo-oophorectomy
downin humans1
1 study
Risk-reducing bilateral salpingo-oophorectomy
downin humans1
Risk-reducing bilateral salpingo-oophorectomy prevents ovarian cancer in humans (Carriers of pathogenic variants in BRCA1, BRCA2, BRIP1, RAD51C, or RAD51D).
“We found that the benefit of RRSO is well-established for pathogenic variants in BRCA1/2 as well as BRIP1 and RAD51C/D”
ReviewCarriers of pathogenic variants in BRCA1, BRCA2, BRIP1, RAD51C, or RAD51D
JCO oncology practice
Effects
3CD44
upin silico1
1 study
CD44
upin silico1
Ovarian cancer increases CD44 in silico (ovarian cancer and aging).
“TREM1, SERPINB2, and CD44 were upregulated, while DST was downregulated”
In silicoovarian cancer and aging
Integrative Analysis Reveals Genes Causal Relation with Ovarian Cancer and aging
Current topics in medicinal chemistry
UCP2
upin silico1
1 study
UCP2
upin silico1
Ovarian cancer increases UCP2 in ovarian cancer.
“PRKCD and UCP2 were significantly upregulated in ovarian cancer.”
In silicoin ovarian cancer
Journal of ovarian research
PRKCD
upin silico1
1 study
PRKCD
upin silico1
Ovarian cancer increases PRKCD in ovarian cancer.
“PRKCD and UCP2 were significantly upregulated in ovarian cancer.”
In silicoin ovarian cancer
Journal of ovarian research
Upstream
11Hypertension
no changein humans1RR 1.06
1 study
Hypertension
no changein humans1RR 1.06
Hypertension showed no clear effect on ovarian cancer in humans (RR 1.06, 95% CI 0.96-1.20).
“There was a risk ratio (RR) of 1.06 (95% CI, 0.96-1.20) for ovarian cancer in patients with hypertension”
Review
Hypertension as a Predictor of Ovarian Cancer Risk: A Systematic Review and Meta-Analysis
Health science reports
Age at menarche
no changein humans1
1 study
Age at menarche
no changein humans1
Age at menarche was not clearly linked with ovarian cancer in humans (age at menarche).
“whereas age at menarche showed no association with ovarian cancer.”
Humansage at menarchefemales
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Mismatch repair genes
no changein humans1
1 study
Mismatch repair genes
no changein humans1
mismatch repair genes showed no clear effect on ovarian cancer in humans.
“Ovarian cancer risk did not differ significantly by gene.”
Reviewfemales
Gene-specific cancer risks in female Lynch syndrome carriers: A copula-based meta-analysis
Maturitas
PRKCD
upin silico1
1 study
PRKCD
upin silico1
PRKCD increases ovarian cancer in ovarian cancer.
“PRKCD facilitates epithelial-mesenchymal transition (EMT), contributing to ovarian cancer progression”
In silicoin ovarian cancer
Journal of ovarian research
Advanced age
upin rats1
1 study
Advanced age
upin rats1
Advanced age increases ovarian cancer in rats (p = 0.047 for formation, p = 0.002 for volume).
“The rates of tumor formation (p = 0.047) and tumor volume (p = 0.002) were significantly higher in the aged rats than in their young counterparts.”
Animals
Regulation of Age-Related Lipid Metabolism in Ovarian Cancer
International journal of molecular sciences
Weight-adjusted-waist index
no changein humans1OR 1.16
1 study
Weight-adjusted-waist index
no changein humans1OR 1.16
Weight-adjusted-waist index was not clearly linked with ovarian cancer in humans (OR = 1.16, 95% CI: 0.48-2.72, p = 0.5359).
“No significant association was found between WWI and the risk of ovarian cancer (OR = 1.16, 95% CI: 0.48-2.72, p = 0.5359).”
Humansfemalesn = 4,144
Association between weight-adjusted-waist index and gynecologic cancers: a population-based study
Frontiers in nutrition
Body mass index
no changein humans1OR 0.97
1 study
Body mass index
no changein humans1OR 0.97
Body mass index was not clearly linked with ovarian cancer in humans (without endometriosis) (OR 0.97, 95% CI 0.91–1.05).
“not associated with the risk among women without endometriosis (OR = 0.97; 95% CI, 0.91-1.05)”
Humanswithout endometriosisBMI 25-<30 kg/m2 versus BMI 18.5-<25 kg/m2females
Effects of risk factors for ovarian cancer in women with and without endometriosis
Fertility and sterility
Progesterone
no changein humans1HR 1.16
1 study
Progesterone
no changein humans1HR 1.16
Progesterone was not clearly linked with ovarian cancer in humans (postmenopausal women) (HR 1.16, 95% CI 0.58-2.33).
“Circulating progesterone levels were not associated with endometrial [tertile (T)3 vs. T1 HR (95% confidence interval): 1.87 (0.85-4.11); P trend = 0.17] or ovarian cancer risk [1.16 (0.58-2.33); 0.73].”
Humanspostmenopausal womenserum12 follow-up yearsfemales
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
LDL cholesterol
no changein humans1
1 study
LDL cholesterol
no changein humans1
LDL cholesterol was not clearly linked with ovarian cancer in humans.
“Overall, no clear patterns were observed for HDL-C, LDL-C, or triglycerides and ovarian cancer risk.”
Humans
Ovarian Cancer Risk in Relation to Blood Cholesterol and Triglycerides
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
HDL cholesterol
no changein humans1
1 study
HDL cholesterol
no changein humans1
HDL cholesterol was not clearly linked with ovarian cancer in humans.
“Overall, no clear patterns were observed for HDL-C, LDL-C, or triglycerides and ovarian cancer risk.”
Humans
Ovarian Cancer Risk in Relation to Blood Cholesterol and Triglycerides
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
All 11Fewer
Associations
94Oral contraceptives
downin humans6HR 0.57–0.75
6 studies
Oral contraceptives
downin humans6HR 0.57–0.75
Oral contraceptives are linked with a lower risk of ovarian cancer in humans (BRCA2 carriers) (HR 0.57, 95% CI 0.35-0.94).
“Oral contraceptive use was associated with a decrease in the risk of ovarian cancer in BRCA2 carriers (HR = 0.57, 95% CI 0.35-0.94, p = 0.028)”
HumansBRCA2 carriersfemalesn = 687
Hormonal contraceptives and cancer risk in women with a BRCA1 or BRCA2 pathogenic variant
Breast cancer (Tokyo, Japan)
Oral contraceptives are linked with a lower risk of ovarian cancer in humans.
“oral contraceptive use for ≥1 year were also associated with reduced risk.”
Humans≥1 yearfemales
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Oral contraceptives are associated with ovarian cancer in humans (Premenopausal women) (HR 0.75, 95% CI 0.61–0.93).
“Breastfeeding for 12 months or longer and oral contraceptive use for 1 year or longer were associated with lower risk in premenopausal women”
HumansPremenopausal womenoral1 year or longerfemalesn = 932,637
Reproductive Shifts and Ovarian Cancer Risk in Women Aged 40 Years or Older
JAMA network open
Oral contraceptives are associated with ovarian cancer in humans (vs. controls without cancer) (p < 0.001).
“whereas full-term pregnancy (p 0.001), breastfeeding (p 0.001), and oral contraceptive use (p 0.001) were less frequent.”
Humansvs. controls without cancerfemales
Kazan medical journal
Oral contraceptives are linked with a lower risk of ovarian cancer in humans (P = 0.79 for trend).
“However, we observed no such attenuation in the oral contraceptive-associated risk reductions (P = 0.79 for trend in HR with increasing age).”
Humansfemalesn = 310,290
Parity and Oral Contraceptive Use in Relation to Ovarian Cancer Risk in Older Women
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Oral contraceptives are associated with ovarian cancer in humans (Current or recent use).
“and a lower risk of colorectal and ovarian cancer.”
ReviewCurrent or recent usefemales
American journal of public health
Parity
downin humans5HR 0.68
5 studies
Parity
downin humans5HR 0.68
Parity is linked with a lower risk of ovarian cancer in humans (compared with nulliparity).
“Compared with nulliparity, having ≥2 births was associated with lower risk.”
Humanscompared with nulliparityfemales
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Parity is associated with ovarian cancer in humans (Premenopausal women) (HR 0.68, 95% CI 0.58–0.79).
“Parity of 2 or more births was associated with lower risk in both groups”
HumansPremenopausal women2 or more birthsfemalesn = 932,637
Reproductive Shifts and Ovarian Cancer Risk in Women Aged 40 Years or Older
JAMA network open
Parity is linked with a lower risk of ovarian cancer in humans (RR = 1.43 among women who had never given birth).
“Subgroup analysis showed that parity may significantly reduce the ovarian cancer risk, which was higher among women who had never given birth (RR = 1.43, p < 0.0025)”
Humansovaryfemales
Hypertension and ovarian cancer risk: a meta-analysis of observational studies
Archives of medical science : AMS
Parity is associated with ovarian cancer in humans (married postmenopausal women) (13.2% lower incidence per additional child (95% CI 11.2–15.3%)).
“ovarian cancer 13.2% (11.2-15.3) and endometrial cancer 10.9% (8.9-12.8) with similar curvilinear relationship.”
Humansmarried postmenopausal womeneach additional child1960–2005femalesn = 385,816
medRxivPreprint
Parity lowers the risk of ovarian cancer in humans.
“parity reduces the risk of OC”
Review
Antioxidants (Basel, Switzerland)
Hormone replacement therapy
upin humans4upin reviews1HR 1.2
5 studies
Hormone replacement therapy
upin humans4upin reviews1HR 1.2
Hormone replacement therapy is linked with a higher risk of ovarian cancer in humans.
“Menopausal hormone replacement therapy use for ≥5 years was also associated with higher risk”
Humans≥5 yearsfemales
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Hormone replacement therapy is associated with ovarian cancer in humans (Postmenopausal women) (HR 1.20, 95% CI 1.07–1.34).
“hormone replacement therapy use for 2 to 5 years (HR, 1.20 [95% CI, 1.07-1.34]) were associated with higher risk.”
HumansPostmenopausal women2 to 5 yearsfemalesn = 1,353,137
Reproductive Shifts and Ovarian Cancer Risk in Women Aged 40 Years or Older
JAMA network open
Hormone replacement therapy is associated with ovarian cancer in humans (vs. controls without cancer) (45.0% vs. 33.6%, p = 0.003).
“The main group more frequently reported the use of postmenopausal hormone replacement therapy (45.0% vs. 33.6%; p = 0.003)”
Humansvs. controls without cancerfemales
Kazan medical journal
Hormone replacement therapy is associated with ovarian cancer in humans (White women) (OR 1.38, 95% CI 1.22–1.57).
“Long-term MHT use, ≥10 years, was associated with an increased ovarian cancer risk for White women (OR = 1.38, 95%CI: 1.22-1.57)”
HumansWhite women≥10 yearsfemales
British journal of cancer
Hormone replacement therapy raises the risk of ovarian cancer.
“The major risk factors for ovarian cancer include older age, genetics, family history, hormone replacement therapy, nulliparity, and dietary fat.”
Review
Epidemiology and risk factors for ovarian cancer
Przeglad menopauzalny = Menopause review
Telomere length
upin humans2downin humans1upin silico1OR 0.67–1.273
4 studies
Telomere length
upin humans2downin humans1upin silico1OR 0.67–1.273
Telomere length is linked with a higher risk of ovarian cancer in humans (OR 1.273, 95 % CI 1.012-1.602).
“The IVW method supported TL as a risk factor for malignant (OR = 1.273, 95 % CI = 1.012-1.602)”
Humans
Causal effects of telomere length on ovarian tumor risk: Insights from genetic evidence
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences
Telomere length is linked with a higher risk of ovarian cancer in humans (OR 1.27, 95% CI 1.01-1.60).
“telomere length and OC (IVW; OR = 1.27, 95%CI: 1.01-1.60, P = .04)”
Humans
Postgraduate medical journal
Telomere length is linked with a lower risk of ovarian cancer in humans (OR 0.67, 95% CI 0.46-0.97).
“women in the top quartile of LTL had an OR for ovarian cancer of 0.67 (95% CI, 0.46-0.97) compared with those in the bottom quartile.”
Humansleukocyte
Prediagnosis Leukocyte Telomere Length and Risk of Ovarian Cancer
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Telomere length raises the risk of ovarian cancer in silico (OR = 1.27, 95% CI: 1.01-1.60).
“telomere length positively associated with increased risk (OR = 1.27, 95% CI: 1.01-1.60, P = 3.90 × 10−2)”
In silico
Journal of ovarian research
Breastfeeding
downin humans3HR 0.86
3 studies
Breastfeeding
downin humans3HR 0.86
Breastfeeding is linked with a lower risk of ovarian cancer in humans.
“Breastfeeding for ≥12 months and oral contraceptive use for ≥1 year were also associated with reduced risk.”
Humans≥12 monthsfemales
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
Breastfeeding is associated with ovarian cancer in humans (Premenopausal women) (HR 0.86, 95% CI 0.77–0.96).
“Breastfeeding for 12 months or longer and oral contraceptive use for 1 year or longer were associated with lower risk in premenopausal women”
HumansPremenopausal women12 months or longerfemalesn = 932,637
Reproductive Shifts and Ovarian Cancer Risk in Women Aged 40 Years or Older
JAMA network open
Breastfeeding lowers the risk of ovarian cancer in humans (premenopausal women) (HR 0.86, 95% CI 0.77–0.96).
“Kim JH et al., reported a significant risk reduction among premenopausal women (hazard ratio 0.86, 95% confidence interval 0.77–0.96)”
Reviewpremenopausal women≥12 months
Impact of Breastfeeding duration on the Risk of Ovarian Cancer: Systematic Review
Saudi Journal of Medical and Pharmaceutical Sciences
Endometriosis
upin humans2HR 2.04
2 studies
Endometriosis
upin humans2HR 2.04
Endometriosis is associated with ovarian cancer in humans (Surgically diagnosed endometriosis versus no endometriosis; adjusted analysis) (HR 2.04, 95% CI 1.83–2.27).
“After adjustment, the hazard of ovarian cancer in individuals with endometriosis vs. those without was 2.04 (95% CI 1.83-2.27 p<0.0001).”
HumansSurgically diagnosed endometriosis versus no endometriosis; adjusted analysis
Are Patients with Endometriosis at an Increased Risk for Gynecologic Malignancy?
Journal of minimally invasive gynecology
Endometriosis is associated with ovarian cancer in humans (vs. controls without cancer) (13.4% vs. 7.5%, p = 0.02).
“endometriosis (13.4% vs. 7.5%; p = 0.02)”
Humansvs. controls without cancerfemales
Kazan medical journal
CA125
mixedin humans1upin silico1
2 studies
CA125
mixedin humans1upin silico1
CA125 predicts ovarian cancer in silico.
“Menopause status, CA125-related interactions, and neutrophil-based interactions were identified as important predictors by SHAP analysis.”
In silico
Indian Journal of Science and Technology
CA125 is associated with ovarian cancer in humans (early detection of ovarian cancer).
“Integration with CA125 may improve sensitivity but can reduce specificity”
Reviewearly detection of ovarian cancer
DNA methylation biomarkers for early detection of ovarian cancer
Molecular biology reports
BRCA2
upin humans2
2 studies
BRCA2
upin humans2
BRCA2 is linked with a higher risk of ovarian cancer in humans (24.1% (95% CI, 15.1-36.6)).
“The lifetime risk of ovarian cancer was 55.0% (95% CI, 48.8-61.9) for a BRCA1 carrier and 24.1% (95% CI, 15.1-36.6) for a BRCA2 carrier.”
Humansfemales
Projected Benefit of Bilateral Salpingo-Oophorectomy by Age in BRCA Carriers
JAMA surgery
BRCA2 is linked with a higher risk of ovarian cancer in humans (pathogenic variant carriers) (29.3% (95% CI, 14.2%-41.7%)).
“and 29.3% (95% CI, 14.2%-41.7%) for BRCA2 pathogenic variant carriers, compared with 1.5% (95% CI, 1.3%-1.7%) in the general population.”
Humanspathogenic variant carriersovaryfemales
Breast and Ovarian Cancer Among Individuals Undergoing BRCA1 and BRCA2 Testing
JAMA network open
BRCA1
upin humans2
2 studies
BRCA1
upin humans2
BRCA1 is linked with a higher risk of ovarian cancer in humans (55.0% (95% CI, 48.8-61.9)).
“The lifetime risk of ovarian cancer was 55.0% (95% CI, 48.8-61.9) for a BRCA1 carrier”
Humansfemales
Projected Benefit of Bilateral Salpingo-Oophorectomy by Age in BRCA Carriers
JAMA surgery
BRCA1 is linked with a higher risk of ovarian cancer in humans (pathogenic variant carriers) (56.0% (95% CI, 40.0%-67.7%)).
“corresponding ovarian cancer incidence was 56.0% (95% CI, 40.0%-67.7%) for BRCA1 pathogenic variant carriers and 29.3% (95% CI, 14.2%-41.7%) for BRCA2 pathogenic variant carriers”
Humanspathogenic variant carriersovaryfemales
Breast and Ovarian Cancer Among Individuals Undergoing BRCA1 and BRCA2 Testing
JAMA network open
PALB2
upin humans2
2 studies
PALB2
upin humans2
PALB2 is linked with a higher risk of ovarian cancer in humans (female carriers of PALB2 PGVs) (5.38% (95% CI 2.94 to 8.26) vs 1.10%).
“cumulative lifetime risk for OC for female carriers of PALB2 PGVs at age 80 years was estimated to be 5.38% (95% CI [2.94 to 8.26])”
Humansfemale carriers of PALB2 PGVsfemales
Age-Specific Ovarian Cancer Risk Among Individuals With Pathogenic Variants in PALB2
JCO precision oncology
PALB2 is associated with ovarian cancer in humans (PALB2 variant carriers; risk depends on family history).
“In PALB2, RRSO is particularly controversial as newer studies consistently demonstrate an increased risk of OC that is dependent on family history”
ReviewPALB2 variant carriers; risk depends on family history
JCO oncology practice
All 94Fewer
Trial sponsors
Company12 trialsPhase 43,678 people
Company11 trialsPhase 34,216 people
Company10 trialsPhase 36,012 people
Company9 trialsPhase 32,689 people
Company7 trialsPhase 32,470 people
Company6 trialsPhase 31,962 people
Company5 trialsPhase 31,142 people
Company5 trialsPhase 3791 people
Funding
93 grants since 2017National Cancer Institute$96MNational Institute on Aging$2.5MGouvernement du Canada | Canadian Institutes of Health ResearchCA$3.9M
Oncoaging and Ovarian Cancer Metastatic Success
American Cancer SocietyUniversity of Notre Dame297K2026–2028
Breast Cancer Research FoundationBikur Cholim Hospital225K2026–2027
Salpingectomy for Ovarian Cancer Risk Reduction: Improving Utilization and Informed Decision-Making
Agency for Healthcare Research and QualityColumbia University Health Sciences$355K2022–2027
National Cancer InstituteHoag Memorial Hospital Presbyterian$541K2026–2031
National Cancer InstituteJohns Hopkins University$453K2022–2027
National Cancer InstituteChildren's Hosp of Philadelphia$611K2026–2031
National Cancer InstituteMassachusetts General Hospital$941K2023–2028
National Cancer InstituteMassachusetts General Hospital$953K2022–2028
Blood-Based Biomarkers for Personalized Risk Assessment of Breast and Ovarian Cancer
National Cancer InstituteUniversity of Tx Md Anderson Can Ctr$672K2023–2028
Trial of Exercise and Lifestyle (TEAL) in Women with Ovarian Cancer
National Cancer InstituteYale University$1.2M2022–2027
How this record changed
Summary rewritten as its findings changed.
As it read before
Advanced age increases ovarian cancer formation and volume in a rat study, while cellular senescence promotes ovarian cancer in a human-cell study. Human cohorts link BRCA1/BRCA2 pathogenic variants and later menopause with higher ovarian cancer risk; telomere-length associations point both ways. Bilateral salpingo-oophorectomy at benign hysterectomy is associated with lower risk.
Summary rewritten as its findings changed.
As it read before
A rat study reports greater ovarian tumor formation and volume with advanced age. Human studies link later menopause and BRCA1/BRCA2 pathogenic variants with higher ovarian cancer risk, and parity with lower risk. Human associations between telomere length and ovarian cancer point both ways.
Summary rewritten as its findings changed.
As it read before
Advanced age increases ovarian tumor formation and volume in a rat study, while reviews link older age with ovarian cancer risk. Human studies associate BRCA1/2 pathogenic variants and obesity with higher risk, and parity and oral contraceptive use with lower risk. Telomere-length associations in humans point both ways.
Summary rewritten as its findings changed.
As it read before
Ovarian tumor formation and volume increase with advanced age in a rat study. Human studies link BRCA1/2 pathogenic variants and higher body mass index with higher ovarian cancer risk, and parity and oral contraceptive use with lower risk. Telomere-length associations point both ways.
Summary rewritten as its findings changed.
As it read before
One human study links BRCA1 and BRCA2 carrier status to increased ovarian cancer risk. A human preprint finds serum CA-125-STn predicts ovarian cancer within five years of sampling, while another human study reports no effect of lactation on ovarian cancer.